Tactiva, Inc.

Biotechnology ResearchNew York, United States2-10 Employees

Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy. We are taking the fight to cancer by developing next generation adoptive cell therapy (ACT) strategies that deliver lethal hits to cancer cells. Our approach provides robust and sustained immune attack on tumors by infusing large numbers of patients’ own T cells that have been re-programed to recognize, attack and destroy cancer cells. The technology used by Tactiva Therapeutics is licensed from Roswell Park Cancer Institute (RPCI). To date, the program has received $23 million in grant support from the National Cancer Institute’s Specialized Programs of Research Excellence (SPORE) Grant and NY Stem Cell Science program (NYSTEM).

Sign up for free to view info

Email Format Employee directory